FDA approves Vivus weight-loss drug Qsymia

Vivus Inc.'s weight-loss drug Qsymia was approved late Tuesday by the Food and Drug Administration after a misstep in the media.

The Mountain View-based company's (NASDAQ: VVUS) drug, a combination of the generic weight loss drug phentermine and the anti-seizure drug topiramate, can be used by obese or overweight adults who have high-blood pressure, diabetes or high cholesterol.

The company's website late Tuesday afternoon featured a screen promoting Qsymia with a sash that said, "Now approved."